NCT04655755View on ClinicalTrials.gov

Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

January 19, 2021

Primary Completion Date

July 20, 2026

Study Completion Date

July 20, 2026

Conditions
Chronic Myelomonocytic LeukemiaMyelodysplastic Syndrome
Interventions
DRUG

Decitabine and Cedazuridine

Given PO

DRUG

Venetoclax

Given PO

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
collaborator

Astex Pharmaceuticals, Inc.

INDUSTRY

collaborator

Genentech, Inc.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER